利用前列腺MRI与危险因素预测临床显著性前列腺癌的模型
研究纳入960例接受前列腺MRI并在其前后6个月内行活检的男性,用年龄、种族、PSA水平及MRI表现建立预测临床显著性前列腺癌的多变量逻辑回归模型和评分系统,并在独立验证队列中评估。验证队列AUC为0.77,校准良好(Hosmer-Lemeshow P=0.58);阈值>5分时敏感度89.5%、阴性预测值70.1%,可避免20.4%的活检。
要点
- 评分>5分时敏感度89.5%、阴性预测值70.1%,可避免20.4%的活检。
- 评分>2分时敏感度98.4%、阴性预测值78.6%,但仅避免4.3%的活检。
- 预测变量为PI-RADS 4分和5分、存在前列腺外侵犯及PSA密度升高。
核心结论
- 该评分模型可能识别绝大多数有临床显著性前列腺癌风险的男性,同时在PSA升高的男性中约每5人可避免1例活检。
研究设计与样本
- 预测模型开发与验证研究,共纳入960例2015年至2019年接受MRI且在其前或后6个月内行活检的男性;开发队列n=632,独立验证队列n=328;参考标准为Gleason评分总和≥7定义为临床显著性前列腺癌。
诊断标准与关键数值
- 临床显著性前列腺癌定义为Gleason评分总和≥7;预测变量为PI-RADS评分4分和5分、存在前列腺外侵犯及PSA密度升高;验证队列AUC为0.77,校准良好(Hosmer-Lemeshow P=0.58)。
临床应用与阅片要点
- 阈值>2分时敏感度98.4%、阴性预测值78.6%,仅避免4.3%的活检(0-2分;328例中14例);阈值>5分时敏感度89.5%、阴性预测值70.1%,避免20.4%的活检(0-5分;328例中67例)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The aim of this study was to develop and validate a predictive model for clinically significant prostate cancer (csPCa) using prostate MRI and patient risk factors.
METHODS: In total, 960 men who underwent MRI from 2015 to 2019 and biopsy either 6 months before or 6 months after MRI were identified. Men diagnosed with csPCa were identified, and csPCa risk was modeled using known patient factors (age, race, and prostate-specific antigen [PSA] level) and prostate MRI findings (location, Prostate Imaging Reporting and Data System score, extraprostatic extension, dominant lesion size, and PSA density). csPCa was defined as Gleason score sum ≥ 7. Using a derivation cohort, a multivariable logistic regression model and a point-based scoring system were developed to predict csPCa. Discrimination and calibration were assessed in a separate independent validation cohort.
RESULTS: Among 960 MRI reports, 552 (57.5%) were from men diagnosed with csPCa. Using the derivation cohort (n = 632), variables that predicted csPCa were Prostate Imaging Reporting and Data System scores of 4 and 5, the presence of extraprostatic extension, and elevated PSA density. Evaluation using the validation cohort (n = 328) resulted in an area under the curve of 0.77, with adequate calibration (Hosmer-Lemeshow P = .58). At a risk threshold of >2 points, the model identified csPCa with sensitivity of 98.4% and negative predictive value of 78.6% but prevented only 4.3% potential biopsies (0-2 points; 14 of 328). At a higher threshold of >5 points, the model identified csPCa with sensitivity of 89.5% and negative predictive value of 70.1% and avoided 20.4% of biopsies (0-5 points; 67 of 328).
CONCLUSIONS: The point-based model reported here can potentially identify a vast majority of men at risk for csPCa, while avoiding biopsy in about 1 in 5 men with elevated PSA levels.
引用
- Lacson R, Haj-Mirzaian A, Burk K, et al. A Model for Predicting Clinically Significant Prostate Cancer Using Prostate MRI and Risk Factors. J Am Coll Radiol. 2024. PMID: 38719106. doi:10.1016/j.jacr.2024.02.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。